Siemens said the has been " substantial progress in the preparation of the unprecedented transaction structure … [and] The separation process is advanced." ...

The firm intends to use the credit facility for liquidity support for its US dollar-denominated commercial paper program and for general corporate purposes.

The expanded panel includes 93 new microorganism-drug combinations, bringing the total panel size to 215, and in conformity with all the most current FDA breakpoints.

The Utrecht, Netherlands-based company recently closed a $70 million funding round and published trial results showing its technology's equivalence to manual blood collection.

The firm's overall revenue rose 8 percent, driven by growth in established pharmaceuticals and medical devices.

Pathologists at academic medical centers are using intentional change-management strategies to overcome some intangible barriers digital uptake.

With the mark, the system, a fully automated blood culture platform meant for diagnosing bloodstream infections, can be sold throughout the EU.

The deal will help CHOP to expand the reach of its diagnostic innovations, allow Labcorp to grow its offerings, and enable the parties to combine resources to accelerate test development.

The test, which leverages technology that mimics a dog's ability to sense disease in humans, analyzes cancer-associated volatile organic compounds found in urine samples.

Last week, readers were most interested in a story about FDA clearing Waters' HPV Self-Collection Kit and HPV Assay acquired from Becton Dickinson.

With the deal, Austin, Texas-based Function adds to its clinical lab offerings, allowing its members to schedule at-home or in-office blood draws.

The parties will work on tests in areas including cancer, genetics, immune disorders, and rare diseases and streamline the path from discovery to national availability.